The ARCH (Age-Related Changes in Hematopoiesis) Project is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim of developing novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and will deploy a large panel of cutting-edge technologies, such as single cell genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their Italian nodes.
ARCH will recruit 15 Early Stage Researchers (ESRs) who will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
The project will be coordinated by Prof. Antonella Ronchi at the University of Milano-Bicocca – Department of Biotechnology and Biosciences (Italy).
The ARCH consortium involves 15 Beneficiaries recruiting the ESR. The 15 Positions are listed here below:
ESR 1 – Università Degli Studi Di Milano-Bicocca (Italy) – POSITION FILLED
Identification of Sox6 and NR2F2 downstream networks controlling normal (and malignant) erythropoiesis
Antonella Ronchi: firstname.lastname@example.org
ESR2 – Academisch Ziekenhuis Groningen (Netherlands) – POSITION FILLED
Physiological HSCs changes during ageing
Gerald De Haan, Leonid Bystrykh: email@example.com
ESR3 – Centre Europeen De Recherche En Biologie Et Médecine (France) – POSITION FILLED
Defining the function of the Helios transcription factor in hematopoietic stem cell ageing
Philippe Kastner, Susan Chan: firstname.lastname@example.org
ESR4 – King’s College London (United Kingdom) – POSITION FILLED
Investigating the role of defective DNA repair mechanisms in HSC aging
John Strouboulis: email@example.com
ESR5 – Flowmetric Europe Spa (Italy) – POSITION FILLED
Dissecting human hematopoietic differentiation by polychromatic flow cytometry and single cell transcriptome analysis
Stefano Di Giovine, Gianluca Carenzo: firstname.lastname@example.org
ESR 6 – Università Degli Studi Di Roma La Sapienza (Italy) – POSITION FILLED
Defining the role of N6-methyladenosine (m6A) in AML cell differentiation
Alessandro Fatica: email@example.com
ESR 7 – Veterinaermedizinische Universitaet Wien (Austria) – POSITION FILLED
Identification of critical effectors of oncoproteins in acute leukemia
Florian Grebien: firstname.lastname@example.org
ESR 8 – Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften (Germany) – new deadline 08/03/2020
The aged dormant HSC compartment under homeostatic and stressed conditions
Nina Cabezas-Wallscheid: email@example.com
ESR 9 – Institut National De La Santé Et De La Recherche Médicale (France) – POSITION FILLED
Characterization of a new epigenetic marker in AML cells
Estelle Duprez: Estelle.Duprez@inserm.fr
ESR 10 – Agencia Estatal Consejo Superior De Investigaciones Cientificas (Spain) – POSITION FILLED
Genetic analysis of PRC1 function in homeostatic and malignant hematopoiesis
Miguel Vidal: firstname.lastname@example.org
ESR 11 – Institut Curie (France) – POSITION FILLED
Hijacking developmental pathways as therapeutic targets in T-cell acute lymphoblastic leukemia (T-ALL)
Christine Tran Quang, Jacques Ghysdael: email@example.com and Jacques.firstname.lastname@example.org
ESR 12 – Tel Aviv University (Israel) – POSITION FILLED
Modeling the role of the thymic stromal lymphopoietin (TSLP) receptor and TSLP in Acute Lymphoblastic Leukemia (ALL)
Shai Izraeli: email@example.com
ESR 13 – Fondazione M. Tettamanti E Menotti De Marchi Onlus (Italy) – POSITION FILLED
Modeling the development and sustainment of pre-leukemia and leukemia target treatment
Gianni Cazzaniga: firstname.lastname@example.org
ESR 14 – Diagenode (Belgium) – POSITION FILLED
Highlighting epigenomics in MLL-rearranged AML
Antonio Soares, Celine Sabatel: email@example.com
ESR 15 – Idryma Iatroviologikon Ereunon Akademias Athinon (Greece) – POSITION FILLED
The role of STAT5 target gene networks in leukemia
Eleni Katsantoni: firstname.lastname@example.org
The Marie Skłodowska-Curie programme offers highly competitive and attractive salary and working conditions. Exact salary will be confirmed upon appointment. In particular it consists of:
– a monthly living allowance: 3,270 euro/month (€39,240/year); this amount is then adjusted through the application of a country correction coefficient to the living allowance of the country in which the researcher is recruited: 106.7% to Austria, 100.0% to Belgium, 115.7% to France, 97% to Germany, 88.7% to Greece, 104.4% to Italy, 107.9% to Netherlands, 139.8% to United Kingdom, 95.4 % to Spain, 106.1% to Israel
– a monthly mobility allowance: 600 euro/month
– a monthly family allowance, if applicable depending on the family situation: 500 euro/month.
It must be noted that the living allowance is a gross EU contribution to the salary costs of the researcher. Consequently, the net salary results from deducting all compulsory (employer/employee) social security contributions as well as direct taxes (e.g. income tax) from the gross amounts. The rate indicated here is for researchers devoting themselves to their project on a full-time basis.
The mobility and family allowance is a fixed amount, regardless of the country of recruitment, and may be taxable depending on the country in which the researcher is recruited.
more details please see Sections 5.1, 5.2 and 5.3 of the Guide for Applicants
Who can apply
Applicants need to fully comply with the following eligibility criteria:
– Applicants must be Early-Stage Researchers (ESRs) who, at the time of recruitment by the host, are in the first four years (full-time equivalent) of their research careers. This is measured from the date when they obtained the degree which formally entitles them to embark on a doctorate.
– Applicants cannot already hold a PhD.
– Applicants can be of any nationality. They are required to undertake physical, transnational mobility: they must not have resided or carried out their main activity in the country of the host institute for more than 12 months in the last three years immediately prior to the reference recruitment date. In the case of researchers with refugee status, they will benefit from a less restrictive mobility rule;
– Applicants must be proficient in both written and spoken English
Applicants for ARCH have to meet the following main criteria:
– Excellent Master’s degree or equivalent qualification in an area relevant to the main scientific themes/objectives/activities of the ARCH Project
– Strong evidence of genuine interest and motivation in scientific research
– Excellent references
– Publications in a relevant research field are desirable
ARCH Project pursues a policy of equal opportunities: amongst equally qualified candidates, care will be taken to ensure gender balance and to recruit researchers from European countries where research is less advanced and/or between Refugees.